Tarlatamab, a First-in-Class DLL3-Targeted Bispecific T-Cell Engager, in Recurrent Small-Cell Lung Cancer: An Open-Label, Phase I Study
Tarlatamab,一种首创的靶向 DLL3 的双特异性 T 细胞衔接剂,用于治疗复发性小细胞肺癌:一项开放标签的 I 期研究
期刊:Journal of Clinical Oncology
影响因子:41.9
doi:10.1200/JCO.22.02823
Paz-Ares, Luis; Champiat, Stephane; Lai, W Victoria; Izumi, Hiroki; Govindan, Ramaswamy; Boyer, Michael; Hummel, Horst-Dieter; Borghaei, Hossein; Johnson, Melissa L; Steeghs, Neeltje; Blackhall, Fiona; Dowlati, Afshin; Reguart, Noemi; Yoshida, Tatsuya; He, Kai; Gadgeel, Shirish M; Felip, Enriqueta; Zhang, Yiran; Pati, Amrita; Minocha, Mukul; Mukherjee, Sujoy; Goldrick, Amanda; Nagorsen, Dirk; Hashemi Sadraei, Nooshin; Owonikoko, Taofeek K